

IRODALOMJEGYZÉK

FORRÁSANYAGOK

1. fejezet: A *Praxis* folyóirat 2005. januári számában megjelent összefoglaló munka átdolgozott formája.
2. fejezet: A *Praxis* folyóirat 2005. februári számában megjelent összefoglaló munka átdolgozott formája.
3. fejezet: A *Praxis* folyóirat 2005. áprilisi számában megjelent összefoglaló munka átdolgozott formája.
4. fejezet: A *Praxis* folyóirat 2005. októberi számában megjelent összefoglaló munka átdolgozott formája.
5. fejezet: A *Magyar Hírlap Biotechnológia mellékletében* 2006 folyamán több részben megjelent írások átdolgozott formája.
6. fejezet: *Az Élet és Irodalomban* 2006. május 5-én megjelent írás.
7. fejezet: A *Népszabadságban* 2006. július 13-án megjelent írás.
8. fejezet: A *Népszabadságban* 2006. augusztus 11-én megjelent írás.
9. fejezet: Az interjú rövidített formája a *Figyelőben* jelent meg 2006. szeptember 14-én.

TOVÁBBI IRODALOM:

- Alam JJ. Apoptosis: Target for novel drugs. *Trends Biotechnol.* 2003. 21:479–83.
- American Diabetes Association: Position statement: Standards of medical care in diabetes. *Diabetes Care.* 2004. 27 (Suppl 1): S15–S35.
- Basta G, Schmidt AM, De Caterina R.: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. *Cardiovasc Res.* 2004. 63:582–92.
- Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications *J. Physiol.* 2004.; 555:589–606.
- Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. *Curr Med Res Opin.* 2004. 20:1559–69.
- Bivalacqua TJ, Champion HC, Hellstrom WJ, Kadowitz PJ. Pharmacotherapy for erectile dysfunction. *Trends Pharmacol Sci.* 2000.;21:484–9.
- Candido R, Srivastava P, Cooper ME, Burrell LM. Diabetes mellitus: a cardiovascular disease. *Curr Opin Investig Drugs.* 2003. 4: 1088–94.
- Chen M, Zsengellér Z, Xiao CY, Szabó C. Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant

- stress: potential role of poly(ADP-ribose) polymerase-I. *Cardiovasc Res.* 2004.;63:682–8.
- Da Ros R, Assaloni R, Ceriello A. Antioxidant therapy in diabetic complications: what is new? *Curr Vasc Pharmacol.* 2004. 2: 335–41.
- Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. *Circulation.* 2004. 109 (23 Suppl 1) III.27–32.
- Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. *J Clin Invest.* 2003.; 112:1049–57.
- Fink MP. Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration? *Crit Care Clin.* 2002.;18:165–75.
- Furchgott RF. The 1989 Ulf von Euler lecture. Studies on endothelium-dependent vasodilation and the endothelium-derived relaxing factor. *Acta Physiol Scand.* 1990.;139:257–70.
- Garcia Soriano F, Virág L, Jagtap P, Szabó E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabó C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. *Nat Med.* 2001. 7: 108–13.

- Gonzalez-Cadavid NF, Ignarro LJ, Rajfer J. Nitric oxide and the cyclic GMP system in the penis. *Mol Urol*. 1999.;3:51–59.
- Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat Med*. 2003. 9: 294–9.
- Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z. Inhibition of interleukin 1 beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. *Proc Natl Acad Sci USA*. 1997.;94:2007–12.
- Haslam RJ, Dickinson NT, Jang EK. Cyclic nucleotides and phosphodiesterases in platelets. *Thromb Haemost*. 1999.;82:412–23.
- Higuchi Y. Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress. *Biochem Pharmacol*. 2003.;66:1527–35.
- Hirsch AT, Duprez D. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. *Vasc Med*. 2003. 8:273–8.
- Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. *Trends Pharmacol Sci*. 2004.; 25:259–64.

- Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. *Biosci Rep.* 1999. 19: 51–71.
- Jagtap P, Szabó C. Poly (ADP-ribose) polymerase inhibitors. *Nature Reviews Drug Discovery.* 2005.; 4: 421–440.
- Kreuter M, Langer C, Kerkhoff C, Reddanna P, Kania AL, Maddika S, Chlichlia K, Bui TN, Los M. Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development. *Arch Immunol Ther Exp (Warsz).* 2004.;52: 141–55.
- Liaudet L, Soriano FG, Szabó C. Biology of nitric oxide signaling. *Crit Care Med* 2000. 28 (Suppl): N37–52.
- Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. *Am J Med.* 2004. 116 (Suppl 5A): 11S–22S.
- Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature.* 2000. 404: 787–90.
- Ogita H, Liao J. Endothelial function and oxidative stress. *Endothelium.* 2004. 11:123–32.

- Padanilam BJ. Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. *Am J Physiol Renal Physiol.* 2003.; 284: F608–27.
- Philchenkov A. Caspases: potential targets for regulating cell death. *J Cell Mol Med.* 2004.; 8: 432–44.
- Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? *Exp Cell Res.* 2003.;283:1–16.
- Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. *Circulation.* 2003.;108:239–44.
- Rosenson RS.. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. *Atherosclerosis.* 2004. 173:1–12.
- Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. *Nat Rev Drug Discov.* 2002.;1:674–82.
- Ruetten H, Badorff C, Ihling C, Zeiher AM, Dimmeler S. Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis-inhibitory effects. *J Am Coll Cardiol.* 2001.; 38:2063–70.
- Son SM, Whalin MK, Harrison DG, Taylor WR, Griendling KK. Oxidative stress and diabetic vascular complications. *Curr Diab Rep.* 2004. 4: 247–52.

- Southan GJ, Szabó C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. *Biochem Pharmacol.* 1996.;51:383–94.
- Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. *Physiol Rev.* 2004. 84:1381–478.
- Sussman DO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. *J Am Osteopath Assoc.* 2004.;104:S11–5.
- Szabó C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virág L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, Groves JT. Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. *Mol Med.* 2002. 8: 571–80.
- Szabó C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R, Chen M, Mabley JG, Kollai M. Angiotensin II-mediated endothelial dysfunction: role of poly-(ADP-ribose) -polymerase activation. *Mol Med.* 2004. 10:28–35.
- Szabó C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A. Poly-(ADP-Ribose) -polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. *Circulation.* 2002. 106: 2680–6.
- Szabó C. Multiple pathways of peroxynitrite cytotoxicity. *Toxicol Lett.* 2003.;140–141:105–12.

- Takemura G, Fujiwara H. Role of apoptosis in remodeling after myocardial infarction. *Pharmacol Ther.* 2004.;104:1–16.
- Tan KT, Watson SP, Lip GY. The endothelium and platelets in cardiovascular disease: potential targets for therapeutic intervention. *Curr Med Chem Cardiovasc Hematol Agents.* 2004. 2:169–78.
- Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. *Hypertension.* 2003. 42: 1075–81.
- Tiefenbacher CP, Kreuzer J. Nitric oxide-mediated endothelial dysfunction—is there need to treat? *Curr Vasc Pharmacol.* 2003. 1:1233–33.
- Van Wijk SJ, Hageman GJ. Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia/reperfusion. *Free Radic Biol Med.* 2005.;39:81–90.
- Virág L, Salzman AL, Szabó C. Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. *J Immunol.* 1998.; 161:3753–9.
- Virag L, Szabó C. The therapeutic potential of poly(ADP-ribose) -polymerase inhibitors. *Pharmacol Rev.* 2002.;54:375–429.
- Voetsch B, Jin RC, Loscalzo J. Nitric oxide insufficiency and atherothrombosis. *Histochem Cell Biol.* 2004. 122:353–367.

- Weissig V, Cheng SM, D'Souza GG. Mitochondrial pharmaceuticals. *Mitochondrion*. 2004.;3:229–44.
- Winkler G, Pál B, Nagybegányi E, Ory I, Porochnavec M, Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. *Arzneimittelforschung*. 1999.49: 220–4.
- Yuan J, Lipinski M, Degterev A. Diversity in the mechanisms of neuronal cell death. *Neuron*. 2003.; 40: 401–13.
- Zheng L, Szabó C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. *Diabetes*. 2004. 53: 2960–7.
- Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. *Endothelium*. 2004. 11: 89–97.